latest update:
[TrialBase DB]

trial summary · NCT07773727

A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy

Trial record from the TrialBase DB dataset, status RECRUITING, condition Immunoglobulin A Nephropathy (IgAN), sponsored by argenx. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07773727phase PHASE2enrollment 120start 2026-11-05

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN. While in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise. The study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.

Source record: https://clinicaltrials.gov/study/NCT07773727

Facts

registry idNCT07773727
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionImmunoglobulin A Nephropathy (IgAN)
sponsorargenx
sponsor classINDUSTRY
enrollment120
start date2026-11-05
primary completion2029-10-29
completion2030-02-18
results postednot reported

Conditions

  • Immunoglobulin A Nephropathy (IgAN)

Interventions

  • ARGX-121
  • Placebo

Countries

  • Japan
  • United States

Intervention types: BIOLOGICAL

Work with this record